Indivior reports record SUBLOCADE revenue ahead of Supernus merger close

Indivior Pharmaceuticals reported third quarter 2026 results on October 29, 2026, as it prepares to complete its merger with Supernus Pharmaceuticals. In August 2026, the companies announced a definitive agreement to combine in an all-stock merger of equals transaction intended to create a diversified, scaled, CNS-focused biopharmaceutical company.¹ In October 2026, Indivior shareholders approved the proposed merger with Supernus.¹ The company said the deal is expected to close on November 2, 2026, after which the combined company will operate as Supernus, Inc. and begin trading on the Nasdaq Global Select Market under the ticker "SUPN" starting November 3, 2026.¹ Separately, in September 2026 Indivior's board declared a special cash dividend that is contingent on the merger closing, according to the company.

On the commercial side, Indivior said as of September 30, 2026, more than 583,000 patients in the U.S. have been prescribed SUBLOCADE since its launch.¹ Total net revenue for the quarter was $356 million, up 13% year-over-year from $314 million.¹ Total SUBLOCADE net revenue reached $267 million, a 22% increase from $219 million in the prior-year quarter.¹ Adjusted EBITDA was $211 million for the quarter, up 76% from $120 million a year earlier.¹

On cash position, the company said it ended the quarter with cash and investments of $332 million.¹ CFO Ryan Preblick said strong cash generation brought cash and investments to $332 million at quarter end, adding to the financial strength the company will bring to the merger with Supernus.¹ Ahead of the merger close, Indivior said it remains on track to achieve its previously communicated full-year 2026 guidance as a standalone organization¹, though it noted that once the merger completes, that guidance will no longer apply.